| Ren, Hong |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Active, not recruiting | 3 | 871 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
NCT05760781: To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B |
|
|
| Terminated | 2 | 9 | RoW | STSG-0002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Sanuo Jiayi Biotechnology Co. LTD | Chronic Hepatitis b | 12/23 | 12/23 | | |
NCT05760703: Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B |
|
|
| Terminated | 2 | 9 | RoW | STSG-0002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Sanuo Jiayi Biotechnology Co. LTD | Chronic Hepatitis b | 12/23 | 12/23 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT04445194: Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine |
|
|
| Active, not recruiting | 1 | 50 | RoW | Recombinant new coronavirus vaccine (CHO cell) low-dose group, Recombinant new coronavirus vaccine (CHO cells) high-dose group, Recombinant new coronavirus vaccine (CHO cells) placebo group | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., The Second Affiliated Hospital of Chongqing Medical University, Beijing Chao Yang Hospital | Coronavirus | 10/20 | 09/21 | | |
NCT05559242: Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients |
|
|
| Not yet recruiting | 1 | 30 | RoW | Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Liver Dysfunction | 06/23 | 07/23 | | |
NCT05851261: Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects |
|
|
| Completed | 1 | 60 | RoW | PA3670 | Zhejiang Palo Alto Pharmaceuticals, Inc. | Chronic HBV Infection | 10/23 | 12/23 | | |
